Skip to main content
TipRanks
Go Ultimate75% OFF

Sprint Bioscience AB (SPRINT) AI Stock Analysis

1 Followers
SE:SPRINT

Sprint Bioscience AB

(Nasdaq OMX AB:SPRINT)

Select Model
Rating:80Outperform
Price Target:SEK 4.50â–²(22.28% Upside)
Action:reiterated
Date:11/14/26

The score is driven mainly by strong financial performance—high margins, solid net income, and strong free cash flow—supported by a debt-free balance sheet. Technicals add moderate support with price above key moving averages and positive (but not overheated) momentum. Valuation is favorable due to a low P/E, though the key risk is earnings stability given historical cyclicality and slightly declining TTM revenue.

Positive Factors
Debt-free balance sheetA debt-free balance sheet reduces solvency and refinancing pressure, which is especially valuable for a biotechnology company funding uncertain development timelines. Rebuilt equity also provides a stronger financial base and greater flexibility to support operations or advance discovery programs.
Negative Factors
Declining TTM revenueA TTM revenue decline indicates that current profitability has not yet been matched by sustained top-line expansion. Without renewed revenue growth, earnings may remain dependent on project timing or mix, making it harder to establish a consistently compounding business trajectory.

Sprint Bioscience AB (SPRINT) vs. iShares MSCI Sweden ETF (EWD)

-50%0%50%100%150%200%SE:SPRINT+145.33%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 388.30M
Dividend Yield
―
Average Volume (3M)
282.09K
Price to Earnings (P/E)
5.5
Beta (1Y)
1.38
Revenue Growth
170.38%
EPS Growth
―
Country
Sweden
Employees
32
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Sprint Bioscience AB Business Overview & Revenue Model

Company Description

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunoth...

Sprint Bioscience AB Financial Statement Overview

Summary

Strong turnaround with sharply positive profitability (TTM net margin ~52%) and solid earnings (~69.9m), backed by robust operating cash flow (~67.5m) and free cash flow (~66.6m) that closely tracks net income. Balance sheet is a key strength with zero debt and rebuilt equity, though results and equity levels have been volatile and TTM revenue is slightly down (~-3.8%), raising durability risk.

Income Statement

78Positive

Balance Sheet

90Very Positive

Cash Flow

84Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue133.91M167.17M65.64M50.48M83.00K35.11M
Gross Profit116.67M97.33M37.30M41.79M-60.91M24.68M
EBITDA73.03M98.40M-17.32M396.00K-60.00M-24.49M
Net Income69.91M91.74M-18.28M-438.00K-60.17M-25.35M
Balance Sheet
Total Assets89.06M136.66M42.05M62.38M37.42M79.14M
Cash, Cash Equivalents and Short-Term Investments77.52M126.70M25.06M49.93M29.49M70.64M
Total Debt000000
Total Liabilities13.15M17.48M32.78M34.60M9.23M8.68M
Stockholders Equity75.92M119.18M9.27M27.77M28.19M70.45M
Cash Flow
Free Cash Flow66.59M83.44M-24.65M20.42M-59.05M-42.82M
Operating Cash Flow67.48M83.53M-23.36M22.87M-59.05M-40.12M
Investing Cash Flow-850.00K-54.00K-1.30M-2.45M0-2.71M
Financing Cash Flow-61.00K18.17M-225.00K24.00K17.90M86.39M

Sprint Bioscience AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price3.68

Price Trends

50DMA3.47Positive
100DMA3.45Positive
200DMA3.23Positive

Market Momentum

MACD0.10Positive
RSI49.64Neutral
STOCH36.36Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Neutral. The current price of 3.68 is below the 20-day moving average (MA) of 3.71, above the 50-day MA of 3.47, and above the 200-day MA of 3.23, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 49.64 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SPRINT.

Sprint Bioscience AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:SPRINT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 363.43M1.9063.09%―――
SE:SPRINTSE:SPRINT80OutperformSEK 388.30M5.4971.44%―170.38%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ELICSE:ELIC48NeutralSEK 164.51M-6.97-56.09%――14.10%
SE:IMMUSE:IMMU48NeutralSEK 222.02M-1.96-19.14%――13.06%
SE:BINVSE:BINV43NeutralSEK 137.53M-0.28-128.54%―-83.67%-50.29%
SE:IVACCSE:IVACC38UnderperformSEK 224.94M-2.19-43.10%―-17.73%18.97%

* Healthcare Sector Average

Performance Comparison

0%100%200%SE:SPRINTSE:BINVSE:ELICSE:IVACCSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:SPRINT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:SPRINTSprint Bioscience AB3.682.24155.56%
SE:BINVBioInvent International AB2.09-27.96-93.04%
SE:ELICElicera Therapeutics AB2.46-2.70-52.27%
SE:IVACCIntervacc AB0.66-0.24-26.34%
SE:IMMUImmunicum AB3.50-1.49-29.79%
SE:CANTACantargia AB1.29-1.94-60.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026